103 related articles for article (PubMed ID: 140180)
21. Abnormal control of growth hormone secretion by opiate systems in acromegalic patients: a study with naloxone and 2-Br-alpha-ergocryptine (CB 154).
Agnati LF; Benfenati F; Frank G; Capelli M; Bernardi P; Calza L
Med Biol; 1981 Feb; 59(1):58-63. PubMed ID: 7266088
[TBL] [Abstract][Full Text] [Related]
22. Growth hormone inhibitory and stimulatory actions of L-dopa in patients with acromegaly.
Hanew K; Sasaki A; Sato S; Goh M; Yoshinaga K
J Clin Endocrinol Metab; 1987 Feb; 64(2):255-60. PubMed ID: 3793848
[TBL] [Abstract][Full Text] [Related]
23. Growth hormone and prolactin release in acromegalic patients following metergoline administration.
Delitala G; Masala A; Alagna S; Devilla L; Lotti G
J Clin Endocrinol Metab; 1976 Dec; 43(6):1382-6. PubMed ID: 1002821
[TBL] [Abstract][Full Text] [Related]
24. Effects of nomifensine on growth hormone and prolactin secretion in normal subjects and in pathological hyperprolactinemia.
Dallabonzana D; Spelta B; Botalla L; Oppizzi G; Silvestrini F; Chiodini PG; Liuzzi A
J Clin Endocrinol Metab; 1982 Jun; 54(6):1125-8. PubMed ID: 7076795
[TBL] [Abstract][Full Text] [Related]
25. The inhibitory effect of dopamine agonists on LH release in women.
Lachelin GC; Leblanc H; Yen SS
J Clin Endocrinol Metab; 1977 Apr; 44(4):728-32. PubMed ID: 576612
[TBL] [Abstract][Full Text] [Related]
26. Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans.
Liuzzi A; Chiodini PG; Oppizzi G; Botalla L; Verde G; De Stefano L; Colussi G; Gräf KJ; Horowski R
J Clin Endocrinol Metab; 1978 Feb; 46(2):196-202. PubMed ID: 108287
[TBL] [Abstract][Full Text] [Related]
27. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.
Chiodini PG; Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG
J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270
[TBL] [Abstract][Full Text] [Related]
28. Dopaminergic stimulation and inhibition of growth hormone secretion in normal man: studies of the pharmacologic specificity.
Bansal SA; Lee LA; Woolf PD
J Clin Endocrinol Metab; 1981 Dec; 53(6):1273-7. PubMed ID: 7028777
[TBL] [Abstract][Full Text] [Related]
29. A physiological role for sporadic interruptions of the dopaminergic tone in the genesis of big mass prolactin pulses.
López FJ; Sánchez-Criado JE; Negro-Vilar A
Endocrinology; 1991 Sep; 129(3):1471-80. PubMed ID: 1874184
[TBL] [Abstract][Full Text] [Related]
30. Pituitary autonomy in hyperprolactinemic secondary amenorrhea: results of hypothalamic-pituitary testing.
Healy DL; Pepperell RJ; Stockdale J; Bremner WJ; Burger HG
J Clin Endocrinol Metab; 1977 May; 44(5):809-19. PubMed ID: 404308
[TBL] [Abstract][Full Text] [Related]
31. The endocrinology of extrapyramidal system disorders.
Kirkpatrick B; Tamminga CA
Neurol Clin; 1988 Feb; 6(1):159-72. PubMed ID: 2967909
[TBL] [Abstract][Full Text] [Related]
32. Acute and chronic estrogen effects upon serum somatomedin activity, growth hormone, and prolactin in man.
Wiedemann E; Schwartz E; Frantz AG
J Clin Endocrinol Metab; 1976 May; 42(5):942-52. PubMed ID: 178687
[TBL] [Abstract][Full Text] [Related]
33. [Huntington's chorea and somatotropic hormone: dynamic explorations in 27 cases (author's transl)].
Destée A; Petit H; Fossati P; Warot P
Rev Neurol (Paris); 1981; 137(1):21-31. PubMed ID: 6453416
[No Abstract] [Full Text] [Related]
34. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
Bell RD; Carruth A; Rosenberg RN; Boyar RM
J Clin Endocrinol Metab; 1978 Oct; 47(4):807-11. PubMed ID: 45469
[TBL] [Abstract][Full Text] [Related]
35. Anomalous growth hormone responses to thyrotropin-releasing hormone and glucose in cirrhotic patients: the effect of metergoline.
Salerno F; Cocchi D; Frigerio C; Colombo AM; Müller EE
J Clin Endocrinol Metab; 1980 Sep; 51(3):641-6. PubMed ID: 6773980
[TBL] [Abstract][Full Text] [Related]
36. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
[TBL] [Abstract][Full Text] [Related]
37. Growth hormone and prolactin responses to thyrotropin-releasing hormone in patients with severe liver disease.
Panerai AE; Salerno F; Manneschi M; Cocchi D; Müller EE
J Clin Endocrinol Metab; 1977 Jul; 45(1):134-40. PubMed ID: 406272
[TBL] [Abstract][Full Text] [Related]
38. A neuroendocrinological investigation of patients with senile demantia of Alzheimer type. Plasma prolactin and GH responses following TRH, sulpiride, L-dopa, and bromocriptine administration.
Fujita M; Shimizu T
Bull Osaka Med Sch; 1986 Oct; 32(2):73-84. PubMed ID: 3122863
[No Abstract] [Full Text] [Related]
39. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
Ishibashi M; Yamaji T
J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
[TBL] [Abstract][Full Text] [Related]
40. Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.
Carey RM; Thorner MO; Ortt EM
J Clin Invest; 1979 Apr; 63(4):727-35. PubMed ID: 438333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
